person · Reporting owner
MacDonald Brian Richard
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Disc Medicine, Inc.IRON · Entity 2273 | Chief Innovation Officer | June 28, 2023 | June 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Disc Medicine, Inc.
Report date June 28, 2023 · Filed June 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,153 |
Reported balance
After 2023-06-28 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-06-28 · Sale · Disposed 2,247 · Balance 25,153 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.61 to $49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4. |
| Common StockSEC Table I · non-derivative | Direct | 23,253 |
Reported balance
After 2023-06-28 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-06-28 · Sale · Disposed 1,900 · Balance 23,253 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.61 to $50.59, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 22,300 |
Reported balance
After 2023-06-28 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2023-06-28 · Sale · Disposed 953 · Balance 22,300 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.62 to $51.235, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 21,564 |
Reported balance
After 2023-06-29 transaction · row 4
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 4 · 2023-06-29 · Sale · Disposed 736 · Balance 21,564 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.87, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 19,334 |
Reported balance
After 2023-06-29 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2023-06-29 · Sale · Disposed 2,230 · Balance 19,334 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.94, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 17,400 |
Reported balance
After 2023-06-29 transaction · row 6
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 6 · 2023-06-29 · Sale · Disposed 1,934 · Balance 17,400 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.96, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 17,200 |
Reported balance
After 2023-06-29 transaction · row 7
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 7 · 2023-06-29 · Sale · Disposed 200 · Balance 17,200 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.23 to $47.25, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 14,277 |
Reported balance
After 2023-06-30 transaction · row 8
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 8 · 2023-06-30 · Sale · Disposed 2,923 · Balance 14,277 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.29, inclusive. |
| Common StockSEC Table I · non-derivative | Direct | 12,876 |
Reported balance
After 2023-06-30 transaction · row 9
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 9 · 2023-06-30 · Sale · Disposed 1,401 · Balance 12,876 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.58, inclusiv |
| Common StockSEC Table I · non-derivative | Direct | 12,276 |
Reported balance
After 2023-06-30 transaction · row 10
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 10 · 2023-06-30 · Sale · Acquired 600 · Balance 12,276 F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.00, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Son | 1,096 |
Reported balance
Holding disclosure · report date 2023-06-28 · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · Balance 1,096 F12: The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Son | 1,096 |
Reported balance
Holding disclosure · report date 2023-06-28 · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · Balance 1,096 F12: The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
| Common StockSEC Table I · non-derivative | IndirectHeld by Son | 1,096 |
Reported balance
Holding disclosure · report date 2023-06-28 · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · Balance 1,096 F12: The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.61 to $49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.61 to $50.59, inclusive.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.62 to $51.235, inclusive.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.87, inclusive.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.94, inclusive.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.96, inclusive.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.23 to $47.25, inclusive.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.29, inclusive.
F10: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.58, inclusiv
F11: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.00, inclusive.
F12: The Reporting Person disclaims any beneficial ownership of the reported shares other than to the extent of any pecuniary interest he may have therein, directly or indirectly.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 600 | $46.76 | $28,057.98 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 10 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,276 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.56 to $47.00, inclusive. Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,401 | $45.45 | $63,676.29 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 9 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,876 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.31 to $45.58, inclusiv Read SEC document |
| June 30, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,923 | $44.85 | $131,101.81 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 8 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,277 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.31 to $45.29, inclusive. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 200 | $47.24 | $9,448.00 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 7 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,200 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.23 to $47.25, inclusive. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,934 | $46.51 | $89,952.27 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 6 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,400 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.04 to $46.96, inclusive. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,230 | $45.49 | $101,452.96 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 5 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,334 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.94, inclusive. Read SEC document |
| June 29, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 736 | $44.37 | $32,656.17 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 4 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,564 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.03 to $44.87, inclusive. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 953 | $50.80 | $48,415.45 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 3 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,300 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.62 to $51.235, inclusive. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 1,900 | $50.38 | $95,730.36 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 2 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,253 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.61 to $50.59, inclusive. Read SEC document |
| June 28, 2023 Filed Jun 30, 2023 22:29 UTC | Disc Medicine, Inc. IRON · Entity 2273 | SaleCommon Stock | 2,247 | $49.24 | $110,649.02 |
DisclosureSEC source: 0000950170-23-031207 · ownership.xml · nonDerivative · entry 1 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,153 F1 · kind: The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on February 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.61 to $49.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (11) to this Form 4. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:15 UTC | Disc Medicine, Inc. IRON · Entity 2273 | GrantStock Option (Right to Buy) · Derivative | 33,847 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0000899243-23-000314 · doc4.xml · derivative · entry 1 MacDonald Brian Richard · CIK 0001952556 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,847 Underlying: Common Stock · 33,847 shares Expires 2032-12-28 F1 · derivative.exercise_date: The shares underlying this option vest in 48 equal monthly installments following December 29, 2022, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.